[go: up one dir, main page]

US20110274701A1 - Composition and method for preventing/decreasing respiratory illness - Google Patents

Composition and method for preventing/decreasing respiratory illness Download PDF

Info

Publication number
US20110274701A1
US20110274701A1 US13/103,559 US201113103559A US2011274701A1 US 20110274701 A1 US20110274701 A1 US 20110274701A1 US 201113103559 A US201113103559 A US 201113103559A US 2011274701 A1 US2011274701 A1 US 2011274701A1
Authority
US
United States
Prior art keywords
composition
respiratory
adherence
virus
animals
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US13/103,559
Other languages
English (en)
Inventor
Bradley M. Mitteness
Connie Phillips
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Camas Inc
Original Assignee
Camas Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Camas Inc filed Critical Camas Inc
Priority to US13/103,559 priority Critical patent/US20110274701A1/en
Assigned to CAMAS INCORPORATED reassignment CAMAS INCORPORATED ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: MITTENESS, BRADLEY M., PHILLIPS, CONNIE
Publication of US20110274701A1 publication Critical patent/US20110274701A1/en
Priority to US13/785,838 priority patent/US9849175B2/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/02—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from eggs

Definitions

  • This invention is directed to microbial adherence inhibitors, in the form of fowl egg antibodies, for substantially preventing the attachment or adherence of colony-forming illness-causing immunogens in respiratory disease complex by inhibiting the immunogen's ability to adhere to the mucous membranes of animals including host food animals, high value nonfood animals, zoological animals, companion animals, laboratory animals or humans, to the method of producing such adherence inhibitors, and to the methods of using such inhibitors.
  • a group of microorganisms form a very complex interaction in the respiratory tract of animals. These animals can be dairy cattle, feedlot cattle, swine, and birds such as chickens and turkeys to name a few.
  • the organisms can vary from animal group to animal group, they are basically bacteria such as Pasteurellae, Mannhiemae, and Haemophilus groups, Mycoplasma , and viruses of the respiratory groups such as bovine respiratory syncytial virus (BRSV), bovine viral diarrhea (BVD), parainfluenza (PI 3 ), infectious bovine rhinotracheitis (IBR), swine influenza, (H 1 N 1 , H 3 N 2 ), fungi and parasites and combinations of the same.
  • BRSV bovine respiratory syncytial virus
  • BVD bovine viral diarrhea
  • PI 3 parainfluenza
  • IBR infectious bovine rhinotracheitis
  • swine influenza H 1 N 1 , H 3 N 2
  • BRDC bovine respiratory disease complex
  • dairy or feedlot cattle a variety of stressful situations such as shipment, weaning, viral infections, bad weather, change in weather, movement in feedlots, poor nutrition, and overcrowding can impair the competence of the immune system and the physical and immunological defenses of the animals.
  • the group of respiratory viruses can weaken the animals and decrease the immunological response of the host, it is the bacterial strains (usually Mannhiema hemolytica or Pasteurella multocida ) that invade the lower respiratory tract leading to bronchopneumonia (BRD) that lead to disease and death of the animal.
  • Bovine respiratory disease is the leading cause of disease related loss in feedlots today. Financial losses attributed to BRD include mortality, medication, veterinary, and labor costs for treatment. Average costs for one treatment average $8.80 per head. Heifers treated for BRD have lower morbidity scores by 37.9%. Animals that are never treated average $11.48 per head higher in net return. The average daily gains differ between treated and untreated animals. The net profit averages $57.48 lower per head for treated animals. BRD has been listed as causing 20.6% of all steer deaths in feedlots.
  • Porcine respiratory disease complex is a major and similar type of disease affecting up to 90% of all swineherds.
  • Mycoplasma hyopneumonia is the primary pathogen commonly associated with the complex secondary pathogens such as Pasteurella multocida types A and D and can cause clinical signs of high fever or impaired growth. Combinations of these organisms can lead to both increase in severity and duration of pneumonia in swine.
  • Porcine reproduction and respiratory syndrome (PRRS) can be another major cause of pneumonia in swine. This can lead to severe reproduction disease with only minimal dose of virulent PRRS stains.
  • Swine respiratory disease can include PRRS virus, swine influenza (H1N1, H3N2) and Mycoplasma hyopneumoniae along with Haemophilus parasuis, Haemophilus suis, Haemophilus planopneumonia, Pasteurella (Mannhiema) haemolytica and Pasteurella multocida (types A & D).
  • PRRS virus swine influenza
  • H1N1, H3N2 Mycoplasma hyopneumoniae along with Haemophilus parasuis, Haemophilus suis, Haemophilus planopneumonia, Pasteurella (Mannhiema) haemolytica and Pasteurella multocida (types A & D).
  • Pneumonic lung lesions may cause poor respiratory health in herds and may affect up to 70 percent of the pigs in a herd.
  • Combinations of vaccinations for viruses and medication for bacteria are needed to help
  • Organisms such as Mycoplasma hyopneumoniae can be a cause of an important chronic respiratory disease called “swine enzootic pneumonia” (SEP). This organism alone can produce severe pneumonia in swine and remains a significant threat to the swine industry.
  • SEP wine enzootic pneumonia
  • Actinobacillus pleuropneumoniae causes “porcine pleuropneumoniae”, resulting in serious financial losses and death.
  • vaccines have been developed, homologous protection has not been demonstrated.
  • 14 serotypes and 2 biotypes have been identified worldwide. Both growing and finishing pigs must be vaccinated to protect herds.
  • avian egg antibody for the diagnosis or treatment of specific conditions has been known.
  • Polson U.S. Pat. No. 4,550,019, is directed to the manufacture and use of fowl egg yolk antibodies for making immunological preparations for the passive immunizations of animals, including humans, as immuno reagents for immunosorbitive processes and in particular for quantitative analytical tests, especially micro assays for diagnostic, pathological, forensic, and pharmacokinectic investigations.
  • Stolle et al U.S. Pat. No. 4,748,018, is directed to a method of passive immunization of mammals using avian egg yolk antibody against any of a variety of antigens using various methods of administration under various conditions and using various compositions incorporating the antibody, after first developing in the mammal a tolerance for the antibody.
  • U.S. Pat. No. 5,080,895 is directed to a specific antibody containing substance from eggs and method of production and use thereof for the treatment of infectious or other diseases, and as additives in food for livestock and poultry, cosmetics, and medicines, and in the field of serodiagnosis.
  • the use of the egg antibody in feeds is to provide an easy means of oral administration of the antibody for the treatment of intestinal infections in livestock or poultry.
  • U.S. Pat. No. 5,196,193, and divisional U.S. Pat. No. 5,443,976, are directed to anti-venom compositions containing horse antibody or avian egg yolk antibody for neutralizing snake, spider, scorpion or jelly fish venom.
  • Stolle et al U.S. Pat. No. 5,753,268, is directed to an anti-cholesterolemic egg vaccine and method for production and use as a dietary supplement for the treatment of vascular disorders in humans and other animals.
  • this invention is directed to a method for the production of a microbial adherence inhibitor for administration to animals, such as host food animals, high value nonfood animals, zoological animals, companion animals, or humans to inhibit or substantially prevent the adherence of colony-forming immunogens and/or disease causing viruses in the respiratory tracts.
  • the microbial adherence inhibitor can be generated by first inoculating female birds, in or about to reach their egg laying age, with the particular target immunogen. Then, after a period of time sufficient to permit the production in the bird of antibody to the targeted immunogen, the eggs laid by the birds are harvested. The yolk and albumin antibody-containing contents of the eggs are separated from the shells.
  • the antibody-containing contents of the eggs may be used directly, placed on an extender, or mixed with carrier material.
  • the antibody can be incorporated into a liquid, mixed into a lick tub, sprayed or squirted into the environment containing the animals.
  • the antibody may also be incorporated into a nasal or an oral spray that can be administered into nasopharyngeal airways or orally.
  • the antibody may also be incorporated onto strips that when placed in the mouth dissolve to release the antibodies into the mouth.
  • the egg antibody adherence inhibiting material maybe stored or shipped for use as needed.
  • the egg contents incorporating the antibody specific to the targeted immunogens are administered to the animals or humans by distributing the antibody material directly or introducing antibody material entrained in air.
  • the material can be introduced into the nasal pharyngeal area of the animal by intranasal application. Aerosol mixtures can be made and administered as a mist over the heads and nostrils of the animals. Another alternative is to mix the material with a carrier and administer as “top dressing” on feed. Special needs can be met by adding the material to water and letting the animals or humans drink the solution.
  • the active material can be added to bulk licks or feed baskets for delivery. Gel-like mixtures can be made using common animal feed mixtures and poured into “lick tubs” (feed additive bulk tubs). Other delivery systems can be adapted for delivery of the active material to the respiratory tract.
  • the present invention relates to a composition for preventing or decreasing respiratory illness.
  • the composition includes adherence inhibiting material produced in eggs laid by female birds, wherein the birds are inoculated with one or more viruses or viral antigens causing the respiratory illness.
  • the adherence inhibiting material is formulated for dispersion into the respiratory tract to prevent or reduce the adherence of the virus causing the respiratory illness to the mucosal membranes of the respiratory tract.
  • the present invention relates to a method of preventing or reducing the incidence of respiratory illness caused by viruses in an animal.
  • the method includes dispersing a composition comprising adherence inhibiting material produced in eggs laid by female birds, wherein the birds are inoculated with one or more viruses or virus antigens causing the respiratory illness, the composition formulated for dispersion into the respiratory tract to prevent or reduce the adherence of the virus causing the respiratory illness to the mucosal membranes of the respiratory tract.
  • Adherence inhibition as referred to herein relates to inhibition of adherence of microbes that prevents or reduces colony and/or plaque formation in the respiratory tract.
  • adherence inhibitors prevent or reduce the ability of microbes such as bacteria to adhere to mucosal membranes and form colonies.
  • adherence inhibitors prevent or reduce the ability of microbes such as viruses to attach and enter cells, thus preventing or reducing the formation of additional viral particles.
  • the present invention is predicated on a method of inhibiting the ability of colony forming microorganisms, such as Pasteurella (Mannhiema) haemolytica, P. multocida , and Haemophilus somnus , Swine influenza, Mycoplasma bovis or M. hyopneumoniae from adhering to the mucous membranes and bronchi and alveolar cells of the respiratory tracts of animals thereby preventing colonization of the microorganisms.
  • the failure of the microorganisms to colonize maintains the immunological defenses of the animals when subjected to stress inducing environments. The result is that the animals have less pneumonic respiratory diseases including shipping fever which cause high mortality of infected animals.
  • the present invention can be used to inhibit respiratory disease causing viruses, particularly influenza viruses, in humans and animals.
  • the disease causing viruses can be, for example, infectious Bovine Rhinotracheitis, (Herpesviridae); Bovine adenovirus 1-7, (Adenoviridae); Bovine Respiratory Coronavirus (Coronaviridae); Bovine Respiratory Syncytial Virus (Paramyxoviridae); Bovine Parainfluenza 3 (Paramyxoviridae).
  • the hen deposits IgY type immunoglobulins in the yolk while depositing IgM and IgA immunoglobulins in the albumin.
  • the albumin helps add stability to the whole egg preparations and helps protect the avian antibodies.
  • the avian IgY immunoglobulins in the yolk tightly bind to, coat, cover and obliterate adherins that attach themselves to their hosts.
  • the IgM and IgA immunoglobulins in the albumin increase binding of the antibody containing material in the mucous tissue of the respiratory tract. This can provide longer sustaining effect of the antibody containing material.
  • the larger antibody containing molecules are more effective in preventing adherence of the targeted immunogen in the respiratory tract of the animal or human.
  • Albumin is a protein that protects the activity of the IgY immunoglobulins thereby increasing their active life in the respiratory tract. Furthermore, a large fraction of the antibodies deposited in the eggs by the hen are against the most recent antigenic challenges to the hen. This all results in the eggs of birds being a most ideal source for large quantities of economically produced highly specific and stable antibodies. While the invention is illustrated by the use of chickens to produce avian antibody, other fowl including turkeys, ducks, geese, ostrich, Emu, pheasant, pigeon, quail, etc. or combination thereof, may be used.
  • groups are obtained of young hen chickens, typically Rhode Island Reds, White Leghorns, sex-linked hybrid crosses or other breeds suited to large egg size, high volume egg production and ease of handling which are about to reach laying age, about 16-19 weeks for chickens, on a schedule predetermined by the amount and timing of final product desired resulting in a steady continuous production stream.
  • each group will enter into an inoculation program using proprietary preparations of specific antigens (immunogens) to which an antibody is desired.
  • the cultures of microorganisms may be obtained from commercial sources such as the American Type Culture Collection (ATCC) or from wild type isolates. The cultures may be used to isolate antigens.
  • the antigens can be prepared as prepared immunogens and may be injected intramuscularly, but preferably injected subcutaneously. In approximately four to five weeks, the average egg collected will contain copious amounts of the desired specific antibody in a readily usable and stable form. The chickens may be reinoculated with the targeted immunogen throughout the egg laying period to maintain the high antibody level.
  • the final antibody products may include some type of innocuous additive, such as dried whey or soy hulls, distillers grains, molasses, soy or rice husks or the like for formulation with feed ration.
  • the antibodies may also be purified, dried and lyophilized for storage for later use. This method provides for the first time, an economical, safe and effective means for controlling respiratory illness causing organisms in beef cattle and dairy herds, swine, chickens, turkeys, companion animals, high value nonfood animals, zoological animals and humans.
  • Immunogen adherence inhibitor and method of making and using same produces specific immunogens to the microbial species listed.
  • the immunogens are used to immunize egg laying avian animals.
  • the immunized hen will lay eggs containing the specific antibodies of the IgM and IgA type in the albumen and IgY type in the yolk.
  • the eggs will be collected and material from the whole cracked egg will be mixed in the proper concentration with a carrier mixture such as molasses, soy oil, DMSO, PBS buffer and Vitamin E solution. This solution is optimized so it can be sprayed, squirted, injected intra-nasally, gelled, or as a top dressing on feed and in lick tubs.
  • the protective material may be sprayed over the animals in the pens or feedlots during the feeding period usually once in the morning and once in the evening.
  • the number of sprayings is determined from testing. Since the material is non-toxic, it is given as needed and as much as needed for a given pen.
  • the preferred method is by direct intra-nasal injection with a spray using 1 ⁇ 2 dose per nostril or a combination of direct nasal spray plus top feed, lick tub, squirt applicators.
  • the product is an all natural preparation that contains specific avian antibodies to the targeted immunogens. These antibodies when attached to the outer surface cell wall, adherin receptors, pilii or pilated structures and capsule, or viral capsid will not allow the organism to attach to the mucous membranes.
  • the microorganisms will not be able to multiply or colonize. It will keep the microorganisms from moving down the respiratory tract and eliminates the ability to cause disease in the lower respiratory tract.
  • the mist By spraying the material, the mist will coat the nasopharynx and prevent the bacteria, viruses or other microorganisms from being spread in water droplets. The mist will also coat the feed and water in the area, again blocking the ability of the pathogen of the organisms to spread from animal to animal.
  • the method of the invention provides for a substantial decrease in animal illness and death in feedlots and pens without the use of antibiotics.
  • the adhesion inhibitor is an avian antibody of extraordinary high specific activity which can very tightly bind to, coat, cover and obliterate these adherins which attach themselves to their hosts with a lock and key type of fit to very unique chemical structures.
  • the avian IgY immunoglobulins in the yolk tightly bind to, coat, cover and obliterate adherins which attach themselves to their hosts.
  • the albumin, IgM and IgA immunoglobulins increase binding in the mucous tissue of the respiratory tract of the antibody containing material which provides longer sustaining effect of the antibody containing material.
  • the larger antibody containing molecules are more effective in preventing adherence of the targeted immunogen in the respiratory tract of the animal or human.
  • Albumin is a protein that protects the activity of the IgY immunoglobulins thereby increasing their active life in the respiratory tract.
  • components of the complement system included in most biological fluids, such as blood, lymph, saliva, tears and to some extent intestinal secretions recognize an antibody attachment as triggers for their many types of defensive activities. Specific antibody attachment and coating combined with the very likely mobilization of many other cellular defense systems, therefore, quickly culminating in the chemical inactivation and ultimately the destruction of the targeted microorganism.
  • the immunogen adherence inhibitor may be directed towards antigens of influenza viruses and other microorganisms that may cause respiratory diseases in animals and/or humans.
  • the viruses can be, for example, Orthomyxoviridae, specifically influenza, H 1 N 1 , H 5 N 1 , H 3 N 2 , or combinations thereof or other types of Hemagglutinin (H) and neuraminidase (N) combinations that are typically identified by an H number and an N number and their mutated strains; the Herpesviridae, specifically, Infectious Bovine Rhinotracheitis, 1 and 5; the Paramyxoviridae, specifically BRSV and PI 3 ; the Arteriviridae, specifically, porcine respiratory and reproductive syndrome virus (PRRSv) and the Adenoviridae, specifically Bovine adenovirus 1, 3, 5, 6, 7.
  • the immunogen adherence inhibitor can include egg-derived antibodies along with a pharmaceutically appropriate carrier and a mucosal bio-adhesive.
  • the immunogen adherence inhibitor can be delivered several times a day as a nasal spray depending on expected exposure to provide longer term or more intense protection.
  • applicators containing the immunogen adherence inhibitor can be carried by individuals expecting to be exposed to virus.
  • Individuals flying on airplanes especially long airplane flights, for example, may carry the nasal spray and administer the spray multiple times during a flight to decrease the chance of infection from a virus or viruses.
  • Individuals could easily apply specific antibodies, immunogen adherence inhibitors, to their upper airways prior to expected exposure by the method of a simple nasal spray. These antibodies would serve as a mucosal protectant to prevent the adherence, colonization and replication of the targeted virus or other microorganism in the human or animal host.
  • the nasal spray may deliver the pharmaceutical composition containing the immunogen adherence inhibitor in a variety of droplet sizes.
  • the droplet size of the particular pharmaceutical composition in the nasal spray may be determined by the location in the respiratory tract that the target microorganism is expected to colonize.
  • the influenza virus, H5N1 generally colonizes deeper in the respiratory tract than the more typical seasonal H3N2 influenza virus.
  • an immunogen adherence inhibitor directed towards H5N1 may be delivered in a smaller droplet size to ensure delivery of the protection deeper in the respiratory tract.
  • Alternative methods for delivering the immunogen adherence inhibitor can also include a mouth rinse or a gargle. Impregnated strips with the immunogen adherence inhibitor designed to dissolve in the mouth to release antibodies can be used to coat the upper airways with the composition containing the immunogen adherence inhibitor.
  • the immunogen adherence inhibitor against an influenza virus may be prepared on a yearly or other periodic time frame before the influenza season.
  • the immunogen adherence inhibitor administered may be based on the circulating strains of the viruses. As circulating strains change or the threat of a new, pandemic virus appears, the product may be updated simply by immunizing new chickens with the newest strain of interest. The birds may begin to deposit antibodies into their eggs specific to the newest strain or strains in as little as two weeks after immunization. In contrast, the prior art methods require a much longer time frame to produce, test and obtain regulatory approval for a new vaccine.
  • the strain of egg laying hen may vary with needs and uses. Any egg laying fowl hens may be immunized including chickens, turkeys, ducks, goose, pigeon, quail, ostrich, emus or any other fowl.
  • the common strains of egg laying chickens were preferred and are usually selected for the number of eggs laid per year, size of egg and ease of housing.
  • Rhode Island Red, White Leghorn, and Red Sex Linked hybrids are the animals of choice based on egg size (large to ex-large, 50-65 gm) and were used for the immunization schedules. The ease of handling the animals and the size and uniformity of the eggs along with the number of eggs laid per hen per year were observed.
  • Pasteurella Multicoda was used as a model bacteria. The organism was isolated from cattle. The ATCC method for rehydration of the stock was followed. The bacteria are re-hydrated in 1.0 ml of TSB. Brain Heart Infusion (BHI, Acumedia) is used to stimulate the PM antigens on the bacterium. Stock TSB is inoculated into BHI Broth and incubated at 37° C. for 18-24 hours. This stimulates somatic and attachment antigens development on the bacteria. Flasks containing BHI Broth are inoculated with the BHI Broth culture. While stirring slowly, flasks are incubated at 37° C. Blood agar plates are streaked for isolation of colonies to confirm the morphology.
  • BHI Brain Heart Infusion
  • Flasks were combined and the material was harvested using centrifugation and sterile saline (0.9%) at approximately 3000 rpm for 30 minutes. The harvest was collected in tubes. Density was checked using spectrophotometer enumeration and McFarland nephelometer standards. The material was diluted to approximately 1 ⁇ 10 9 per ml. Four percent (4%) sodium deoxycholate (Difco) solution was added as a 1:1 ratio with culture in 0.9% sterile saline (Herzberg, 1972) and stirred for approximately 18 hours at room temperature (22° to 24° C.). The material was centrifuged to remove whole cells. Supernatant was used as stock for PM antigen. Dry weight was determined at approximately 14.9 mg/ml. The product is diluted in sterile PBS, pH 7.4 to 1 mg/ml for PM Immunogen.
  • Difco sodium deoxycholate
  • Stock P. Haemolytica was used for PH antigen.
  • the organism was isolated from cattle.
  • the ATCC method for rehydration of the stock was followed.
  • the bacteria were re-hydrated in 1.0 ml of TSB. Brain Heart Infusion (BHI, Acumedia) and used to stimulate the PM antigens on the bacterium.
  • Stock TSB was inoculated into BHI Broth and incubated at 37° C. for 18-24 hours. This stimulates somatic and attachment antigen development on the bacteria.
  • Flasks containing BHI Broth were inoculated with the BHI Broth culture. The flasks were incubated at 37° C. while stirring slowly. Good growth was seen after 22 hours.
  • Stock Haemophilus sommus (ATCC 43626) was used as stock bacterial culture for HS antigen. The organism was isolated from cattle. The ATCC method for rehydration of the stock was followed. The bacteria were re-hydrated in 1.0 ml of TSB. ATCC medium: 814 GC Medium was used to stimulate the HS antigens on the bacterium. Stock TSB was inoculated into 814 GC Medium and incubated at 37° C. and 5% CO 2 for 18-24 hours. This stimulates somatic and attachment antigen development on the bacteria. Good growth was seen after 22-48 hours. Blood agar plates were streaked for isolation of colonies to confirm the morphology.
  • Flasks were combined and the material is harvested using centrifugation and sterile saline (0.9%) at approximately 3000 rpm for 30 minutes. The harvest was collected in tubes. Density was checked using spectrophotometer enumeration and McFarland nephelometer standards. The material was diluted to approximately 1 ⁇ 10 9 per ml. Four percent (4%) sodium deoxycholate (Difco) solution is added as a 1:1 ratio with culture in 0.9% sterile saline (Herzberg, 1972) and stirred for approximately 18 hours at room temperature (22° to 24° C.). The material was centrifuged to remove whole cells. Supernatant was used as stock for HS antigen. Dry weight was determined. The product was diluted in sterile PBS, pH 7.4 to 1 mg/ml for HS Immunogen.
  • Difco sodium deoxycholate
  • Stock Haemophilus suis (ATCC 19417, H. parasuis ) was used as stock for HSa antigen. The organism was isolated from swine. The ATCC method for rehydration of the stock was followed. The bacteria were re-hydrated in 1.0 ml of TSB.
  • PH, PM, HS and HSa ELISA Ninety-six well assay plate (flat bottom Costar) were coated using 100 ⁇ g/ml with various concentration of antigens (10 ⁇ g-200 ⁇ g/ml) in carbonate buffer, ph 9.6. Plates were incubated between 22.degree. to 37.degree. C. for up to 18 hours. The wells were aspirated to prevent cross-contamination. The plates were blocked with 390 ⁇ l/well of 0.5% BSA and incubated at 37° C. for 1 hour. Plates were coated using alternative rows of positive or negative for controls. Plates were rinsed one time with wash buffer containing TweenTM. 20.
  • Eggs were selected at various periods in the immunization period for monitoring antibody responses to the specific antigens. Selected chickens were monitored at day 0 and continued on a monthly basis after the fourth month. The whole egg was collected from the shell and then a 1 ml sample was taken. This sample was then extracted with buffer to analyze the antibody content. The standard ELISA's for the PH, PM, HS and HSa immunogens were used for analysis. The negative readings were subtracted from the OD readings.
  • Pasteurella Haemophilus Batch Liquid Immunogen Signal/Noise Immunogen Signal/Noise Batch #1 0.347 5.32 0.111 2.68 Batch #2 0.188 2.92 0.175 2.93 Batch #3 0.272 2.98 0.138 1.91
  • the manufacturing process for the lick tubs is very simple and straightforward.
  • the manufacture of this example was done by adding prepared wet material and distillers condensed syrup to standard tubs to adjust the moisture content upward.
  • DDGS corn gluten meal, wet cake, mold inhibitor and premix were placed in a 5-ton mixer truck and mixed for 5 minutes. Then the material and Molasses were added. This was mixed for 30 minutes. The resulting material weighed approximately 5,030 pounds. This mixture was unloaded through a side discharge chute into twenty-eight 200-pound plastic tubs and then compressed into a solid material. The tubs were then cured for 48 hours into a very hard, dark brown product with a somewhat yeasty, sweet odor.
  • one tub was placed near the cattle in a pen of one hundred ninety-seven 600-pound steers.
  • the cattle in the test feedlot were very interested in this material. They visited the tubs several times a day. Consumption was about 7.7 grams/head/day. It is anticipated that per head consumption would have been somewhat higher if more tubs were placed in the pen.
  • Top Dressing Specific whole egg was collected from hens immunized with PH, PM, HS and HAs antigens in equal amounts for a total of 7-9 L.
  • the whole egg material was added to 2 L of PBS, pH 7.4, 4.5 L of molasses, and 4 L of distilled water. This was mixed well and preservatives such as food grade vitamin E, vanilla, sodium benzoate, potassium sorbate and sodium citrate were added to prevent microbial growth and extend shelf-life. The total amount is 18 L.
  • the mixture was stirred to get a homogenous solution.
  • the mixture was then pasteurized in a Food Pasteurizer from The Schlueter Company. The material was cooled and stored at 4° C. until used.
  • This material was poured on top of the feed as needed. It was distributed once every 7 days for a total of three applications.
  • any microorganism which colonizes the nasal pharyngeal region of the respiratory tract of its host must possess the capability of sticking or adhering to the surface of the mucus membranes in order to multiply.
  • the respiratory pneumonia complex organisms such as Pasteurella multocida, M. haemolytica, Haemophilus somnus , Swine influenza viruses and Mycoplasma bacteria are no exception to the rule.
  • Other microorganisms from the fungi and parasite groups are included in organisms that may cause respiratory problems in animals or humans.
  • the adherence inhibitor of this invention strongly interferes with adherence and on a cumulative basis, thereby prevents the specific targeted microorganism from colonizing, and multiplying and moving down the respiratory tract and infecting the lower tract including the lungs.
  • the product essentially supplies the host with specific antibody preparation designed not to cure any disease in the animal but merely to dislodge any resident microorganism and to prevent the attachment of any newly introduced microorganism in the upper respiratory tract.
  • the adherence inhibitor has no direct effect on the host itself, is all natural, leaves absolutely no undesirable residue in the animals, and thus has no effect whatsoever on the ultimate food products.
  • the microorganism since the microorganism is prevented from multiplying, it will over time (for example 21-30 days) disappear through natural degradation from mucus of the animal, eliminating the significant potential source of contamination in the feedlot. Properly managed, the risk of cross contaminating other animals throughout the feedlot is lowered and essentially eliminated. Similar applications could be developed for companion animals, zoological animals or nonfood animals or humans. They too have respiratory problems.
  • an antibody formulation was also offered via a lick tank formula (3 ml/pound). All observations were confirmed and finalized by at least 30 days on feed.
  • NP is effective at reducing respiratory disease incidence and resulting death loss when it is a component of an integral health program for receiving feedlot cattle.
  • the swine influenza virus was isolated from herds of swine with endemic influenza episodes. Swabs were taken from varied animals within the herd(s) and transported in viral transport medium to the laboratory for further culture. Each swab culturette fluid was then sterile filtered through a 0.2 ⁇ sterile syringe filter (Pall). The filtered supernate was then placed on confluent monolayers of either or both Swine Kidney cells or MDCK (Madin-Darby canine kidney) cells. Initial culture work was in Falcon T-25 sterile cell culture flasks. Cells were grown in Dulbecco High Glucose Medium (DME) with glutamine and 5% calf serum (Hyclone, Inc).
  • DME Dulbecco High Glucose Medium
  • CPE cytopathology
  • Cytopathology typical of influenza was detected in 5 of 8 cultures. All culture flasks were frozen at ⁇ 70° C. to rupture all cells and free virus; this freeze-thaw was repeated 3 times. After the final freeze-thaw, the fluids were aliquoted into sterile 50 ml centrifuge tubes and centrifuged at 2500 ⁇ G for 10 minutes to spin out cell fragments and debris. The resultant supernate was then aliquoted into sterile storage tubes for testing and identification studies.
  • Swine Kidney or MDCK cell cultures were prepared in large flasks (Falcon T75 or T225) and grown in DME High Glucose with 5% calf serum. The growth medium was decanted and a 5-10 ml aliquot of the virus fluids was added. This material was allowed to adsorb for a minimum of 30 minutes and no longer than 60 minutes at 37° C., 4% CO 2 . The virus laden fluids were then removed from the cell layer and fresh DME media without serum was added to each flask.
  • Fluids were inactivated by formaldehyde, betapropiolactone (BPL) or binary ethylene amine (BEI) for a minimum of 24 hours.
  • BPL betapropiolactone
  • BEI binary ethylene amine
  • the BEI was the preferred method of inactivation for this virus after studies. It was used for all subsequent work. After 24 hours, the pH was adjusted to 7.2-7.4 and the fluids were adjuvanted with an oil emulsion (MVP Labs).
  • the Infectious bovine respiratory virus was isolated from a commercial vaccine.
  • the vaccine was rehydrated with sterile water for injection.
  • Samples for titration were extracted and placed into sterile 15 ml conical tubes (Falcon).
  • the remainder of the vaccine fluids was inactivated with binary ethylene amine (BEI) for a minimum of 8 hours and a maximum of 24 hours.
  • BEI binary ethylene amine
  • the inactivated fluids were then pH adjusted to 7.2 ⁇ 0.2.
  • the inactivated fluids were then adjuvanted with an oil-water emulsion (MVP Labs).
  • the bovine adenovirus strains were received from the National Animal Disease Center and the Center for Veterinary Biologics. Each strain was grown on either Vero cells or Madin-Darby Bovine Kidney cells. The frozen cultures received were thawed and added directly to monolayer cultures of either Vero or MDBK cells. The cultures were maintained in DME high glucose medium with 2% calf serum (HyClone Labs). Each culture was maintained for a minimum of 7 days or until cytopathic effect (CPE) typical of an adenovirus infection was observed. Two or more T-75 flasks (Falcon) of each were prepared. When CPE reached 80% or cultures were 7 days old, all cultures were moved into a ⁇ 70° C.
  • CPE cytopathic effect
  • each culture was decanted into sterile 250 milliliter centrifuge tubes and centrifuged at 12,000 ⁇ g to pellet any cell debris. All supernate fluids were pooled, by strain, sampled for titer and stored in sterile flasks until needed for immunization.
  • Each of the viral isolates was tested on the appropriate cell substrate in 96 well microtiter plates (Falcon).
  • the swine influenza virus preps were tested on MDCK cells in DME High glucose medium (Hyclone) in 2% calf serum. The virus was titered through 2-fold dilutions up to 10 wells to determine live virus titer.
  • the SIV isolates were also tested by PCR to determine strain and quantity. The strain determinant was an H3N2. Further studies with the SIV for live virus titer and virus neutralization were conducted by hemagglutination and hemagglutination inhibition, respectively, testing in 96 well microtiter plates (conical bottom, CoStar).
  • the Infectious Bovine Rhinotracheitis virus was tested in 96 well microtiter plates (flat bottom Falcon). The sample was titered on MDBK (Madin Darby Bovine Kidney cells, Center for Veterinary Biologics, Ames, Iowa). The virus was titered through 2-fold dilutions up to 10 wells to determine live virus titer. Dilutions of the virus were also tested by the plaque assay method for both live virus titer and virus neutralization.
  • Antibodies from Eggs from immunized hens were tested for potency on a weekly basis. The method of testing was dependent upon the immunogen under study.
  • the SW assay was typically an HAI test for the neutralization of the hemagglutinin of the SIV.
  • Other viruses such as the IBR, BRSV, Bovine adenoviruses and paramyxoviruses were tested for virus neutralization on MDBK cells in either a plaque assay method (IBR) or in a 96 well microtiter plate method.
  • the testing resulted in antibody neutralizing responses, when calculated against non-immunized antibody preparations, of 1:8-1:16 using a plaque reduction assay criterion of 80-90% to establish the end point.
  • the USDA standard for passive immunity titers from inactivated vaccines is a 1:2 titer.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
US13/103,559 2003-02-19 2011-05-09 Composition and method for preventing/decreasing respiratory illness Abandoned US20110274701A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US13/103,559 US20110274701A1 (en) 2010-05-07 2011-05-09 Composition and method for preventing/decreasing respiratory illness
US13/785,838 US9849175B2 (en) 2003-02-19 2013-03-05 Composition and method for preventing/decreasing respiratory illness

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33242110P 2010-05-07 2010-05-07
US13/103,559 US20110274701A1 (en) 2010-05-07 2011-05-09 Composition and method for preventing/decreasing respiratory illness

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US10/775,557 Continuation US9701737B2 (en) 2003-02-19 2004-02-10 Immunogen adherence and method of making and using same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US13/785,838 Continuation US9849175B2 (en) 2003-02-19 2013-03-05 Composition and method for preventing/decreasing respiratory illness

Publications (1)

Publication Number Publication Date
US20110274701A1 true US20110274701A1 (en) 2011-11-10

Family

ID=44902084

Family Applications (2)

Application Number Title Priority Date Filing Date
US13/103,559 Abandoned US20110274701A1 (en) 2003-02-19 2011-05-09 Composition and method for preventing/decreasing respiratory illness
US13/785,838 Expired - Fee Related US9849175B2 (en) 2003-02-19 2013-03-05 Composition and method for preventing/decreasing respiratory illness

Family Applications After (1)

Application Number Title Priority Date Filing Date
US13/785,838 Expired - Fee Related US9849175B2 (en) 2003-02-19 2013-03-05 Composition and method for preventing/decreasing respiratory illness

Country Status (9)

Country Link
US (2) US20110274701A1 (es)
EP (1) EP2566521A4 (es)
CN (1) CN102933232A (es)
AU (1) AU2011249882A1 (es)
BR (1) BR112012028315A2 (es)
CA (1) CA2798151A1 (es)
MX (1) MX2012012915A (es)
WO (1) WO2011140550A2 (es)
ZA (1) ZA201209198B (es)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014143781A1 (en) 2013-03-15 2014-09-18 Camas Incorporated Methods and compositions for reducing microorganisms in the oropharynx, nasopharynx and oral cavities
US11168127B1 (en) * 2015-12-01 2021-11-09 Camas Incorporated Pathogen specific avian antibodies in the neonatal mammal
WO2021226358A1 (en) * 2020-05-08 2021-11-11 Camas Incorporated Reduction of viral disease transmission by avian antibodies
US20220296698A1 (en) * 2018-12-12 2022-09-22 Cambridge Technologies Llc Universal influenza vaccine

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9701737B2 (en) 2003-02-19 2017-07-11 Camas, Incorporated Immunogen adherence and method of making and using same
CA2798151A1 (en) * 2010-05-07 2011-11-10 Camas Incorporated Immunogen adherence and method of making and using same
JP2023545851A (ja) * 2020-10-19 2023-10-31 カマス インコーポレイテッド 感染性疾患の伝播を減少させるために受動免疫を使用する方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040161427A1 (en) * 2003-02-19 2004-08-19 Peter Nash Immunogen adherence and method of making and using same
WO2007068154A1 (fr) * 2005-10-31 2007-06-21 Jason Medical Group (Far East) Ltd Principe de modulation de signal dans une amplification classe d et son circuit
US20070218114A1 (en) * 2004-06-12 2007-09-20 Passionfor Life Healthcare Limited Soluble Strip for Oral or Topical Administration
US20110033544A1 (en) * 2009-05-15 2011-02-10 Shin Nippon Biomedical Laboratories, Ltd. Intranasal pharmaceutical compositions with improved pharmacokinetcs
US20110166328A1 (en) * 2008-09-02 2011-07-07 Huan Nguyen Avian Antibodies Specific to Influenza Virus and Technologically Simple Methods of Their Manufacture and Use

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4166867A (en) 1978-02-09 1979-09-04 Ralston Purina Company Palatability in horse feeds
US4550019A (en) 1978-03-22 1985-10-29 South Africa Inventions Development Corporation Manufacture and use of fowl egg antibodies
US4748018A (en) * 1984-02-07 1988-05-31 Stolle Research & Development Corp. Method of passive immunization of mammals using avian antibody
US5753268A (en) 1982-06-03 1998-05-19 Dcv Biologics, L.P. Anti-cholesterolemic egg, vaccine and method for production, and use
GB8405530D0 (en) 1984-03-02 1984-04-04 Lysons R J Vaccine for swine dysentery
EP0225254B1 (en) 1985-11-25 1994-03-16 Ghen Corporation Specific antibody-containing substance from eggs and method of production and use thereof
JPS62175426A (ja) * 1986-01-27 1987-08-01 Kazufumi Shimizu 抗体及びこれを有効成分とするスプレ−剤
US5196193A (en) 1989-10-31 1993-03-23 Ophidian Pharmaceuticals, Inc. Antivenoms and methods for making antivenoms
US5556744A (en) 1992-05-29 1996-09-17 The Trustees Of The University Of Pennsylvania Methods and compositions for diagnosing and treating certain HIV infected patients
US6337070B1 (en) 1993-04-29 2002-01-08 Takara Shuzo Co., Ltd. Polypeptides for use in generating anti-human influenza virus antibodies
US5367054A (en) 1993-04-12 1994-11-22 Stolle Research & Development Corp. Large-scale purification of egg immunoglobulin
US6068862A (en) 1993-06-30 2000-05-30 Taiyo Kagaku Co., Ltd. Tea-derived feed additive and animal feed containing the same
US5420253A (en) * 1993-09-09 1995-05-30 Willmar Poultry Company, Inc. Method for purifying egg yolk immunoglobulins
US5585098A (en) 1993-11-23 1996-12-17 Ovimmune, Inc. Oral administration of chicken yolk immunoglobulins to lower somatic cell count in the milk of lactating ruminants
AU734576B2 (en) * 1996-08-02 2001-06-14 Elan Pharmaceuticals, Inc. Voltage-gated calcium channel antagonist and methods
US6086878A (en) 1997-08-21 2000-07-11 Dcv, Inc. Method of increasing muscle protein and reducing fat in animals
US20020012666A1 (en) * 1998-11-05 2002-01-31 Hellen Chaya Greenblatt A method for increasing weight gain and feed efficiency
US7241443B1 (en) 1999-07-15 2007-07-10 Camas Incorporated Immunogen adherence inhibitor and method of making and using same
FR2810550B1 (fr) * 2000-06-27 2004-10-08 Medibrevex Nouvelle formes galeiques solubles d'oeufs de caille a usage medicamenteux pour lavage oculaire et nasale et leurs procedes de fabrication
WO2002018239A1 (en) * 2000-08-28 2002-03-07 Traylor Keith J Snap-on sprayer assembly for spraying sweetened compositions
CN1819844B (zh) * 2003-02-19 2012-02-22 彼得·纳什 免疫原粘附抑制剂及其制备和使用方法
US20090306347A1 (en) * 2005-08-29 2009-12-10 Japan Science And Technology Agency Antibody produced using ostrich and method for production thereof
CA2798151A1 (en) * 2010-05-07 2011-11-10 Camas Incorporated Immunogen adherence and method of making and using same

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040161427A1 (en) * 2003-02-19 2004-08-19 Peter Nash Immunogen adherence and method of making and using same
US20070218114A1 (en) * 2004-06-12 2007-09-20 Passionfor Life Healthcare Limited Soluble Strip for Oral or Topical Administration
WO2007068154A1 (fr) * 2005-10-31 2007-06-21 Jason Medical Group (Far East) Ltd Principe de modulation de signal dans une amplification classe d et son circuit
US20110166328A1 (en) * 2008-09-02 2011-07-07 Huan Nguyen Avian Antibodies Specific to Influenza Virus and Technologically Simple Methods of Their Manufacture and Use
US20110033544A1 (en) * 2009-05-15 2011-02-10 Shin Nippon Biomedical Laboratories, Ltd. Intranasal pharmaceutical compositions with improved pharmacokinetcs

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Derwent ACC-NO: 2007-675334 translation of WO 2007068154. June 2007 *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014143781A1 (en) 2013-03-15 2014-09-18 Camas Incorporated Methods and compositions for reducing microorganisms in the oropharynx, nasopharynx and oral cavities
US9655962B2 (en) 2013-03-15 2017-05-23 Camas Incorporated Methods and compositions for reducing microorganisms in the oropharynx, nasopharynx and oral cavities
US11168127B1 (en) * 2015-12-01 2021-11-09 Camas Incorporated Pathogen specific avian antibodies in the neonatal mammal
US20220296698A1 (en) * 2018-12-12 2022-09-22 Cambridge Technologies Llc Universal influenza vaccine
US11771756B2 (en) * 2018-12-12 2023-10-03 Cambridge Technologies Llc Universal influenza vaccine
US12102674B2 (en) 2018-12-12 2024-10-01 Cambridge Technologies Llc Universal influenza vaccine
WO2021226358A1 (en) * 2020-05-08 2021-11-11 Camas Incorporated Reduction of viral disease transmission by avian antibodies

Also Published As

Publication number Publication date
AU2011249882A1 (en) 2013-01-10
CA2798151A1 (en) 2011-11-10
MX2012012915A (es) 2013-05-06
US20130183286A1 (en) 2013-07-18
WO2011140550A3 (en) 2012-03-08
EP2566521A4 (en) 2013-11-27
WO2011140550A2 (en) 2011-11-10
ZA201209198B (en) 2013-08-28
BR112012028315A2 (pt) 2016-10-25
US9849175B2 (en) 2017-12-26
CN102933232A (zh) 2013-02-13
EP2566521A2 (en) 2013-03-13

Similar Documents

Publication Publication Date Title
US10407494B2 (en) Immunogen adherence and method of making and using same
US9849175B2 (en) Composition and method for preventing/decreasing respiratory illness
US8926980B2 (en) Compositions against bacterial toxins
US8828422B2 (en) Stabilized liquid egg material for extended shelf life
US5807551A (en) Method to provide artificial passive immunity in birds
JPS63307828A (ja) ニューカッスル病ウイルスワクチン及びその適用方法
US20110129479A1 (en) Immunogen selection directed in immunoglobulin packages in plasma and colostrum and method of making and using same
US20120308579A1 (en) Method of making and using a composition for delivering viral immunogen immunoglobulin inhibitor to the nasal pharyngeal membrane
CN1819844B (zh) 免疫原粘附抑制剂及其制备和使用方法
KR101411995B1 (ko) 돼지 소모성 질병의 치료 또는 예방을 위한 젖소 초유 항체 조성물
KR101622554B1 (ko) 면역항체를 이용한 강아지질병의 치료용 조성물의 제조방법
NZ235906A (en) Milk and eggs containing antibodies to honey allergens.
US20210252149A1 (en) Composition and Methods for Treating Infectious Agents Using Pathogen-specific Antibodies
HK1182024A (en) Immunogen adherence and method of making and using same
US20260041766A1 (en) Systems and methods for producing antibodies
HK1087949B (en) Immunogene adherence and method of making and using the same
Ramadan DL-Methionine: An immunopotentiator in Mycoplasma gallisepticum challenged broilers treated with Pulmotil AC®
KR101158039B1 (ko) 면역 초유 및 면역 난황이 복합된 면역증강 조성물
WO2024030503A1 (en) Systems and methods for producing antibodies
Pande et al. Newcastle disease, Infectious bronchitis and Infectious coryza
KR20030055314A (ko) 칠면조 비기관지염에 대한 난내 보호를 제공하기 위한방법 및 백신

Legal Events

Date Code Title Description
AS Assignment

Owner name: CAMAS INCORPORATED, MINNESOTA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:MITTENESS, BRADLEY M.;PHILLIPS, CONNIE;REEL/FRAME:026623/0133

Effective date: 20110608

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION